cas 455-14-1|| where to buy 4-(Trifluoromethyl)aniline

Nom du produit:4-(Trifluoromethyl)aniline

IUPAC Name:4-(trifluoromethyl)aniline

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM253041-1000g	in stock	Ǚľ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 455-14-1 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:455-14-1; Formule moléculaire:C7H6F3N; Point de fusion:-; Code SMILES:C1=C(C(F)(F)F)C=CC(=C1)N; Densité:

: Numéro de catalogue:CM253041; Poids moléculaire:161.13; Point d'ébullition:190°C at 760 mmHg; N° Mdl:MFCD00064396; Stockage:Keep in a tight container and store at ambient temperature

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Obicetrapib; The elevated low-density lipoprotein cholesterol (LDL-C) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD), and heterozygous familial hypercholesterolemia (HeFH). Cholesteryl ester transfer protein (CETP) transports cholesterol from good high-density lipoprotein cholesterol (HDL-C) to low-density lipoprotein cholesterol (LDL-C). NewAmsterdam’s Obicetrapib is a novel, selective CETP inhibitor to address the limitations of current treatments.
Obicetrapib is under investigation in phase III clinical trials as a monotherapy product, and in phase II studies as a fixed dose combination with Ezetimibe.